×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IONS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
11:14 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/2
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
12/1
11:37 am
ions
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
12/1
09:22 am
ions
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
12/1
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
11/18
09:24 am
ions
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
Low
Report
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
11/17
06:35 am
ions
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
Low
Report
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
11/15
06:41 am
ions
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
Low
Report
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
-2.9%
ionis pharmaceuticals, inc.
7/30/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
4.5%
ionis pharmaceuticals, inc.
4/30/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
1.4%
ionis pharmaceuticals, inc.
2/19/2025
07:00 am
IONS
ionis pharmaceuticals, inc.
BEAT
Report
-1.6%
ionis pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
10/30
11:02 am
Reiterates
Strong-Buy
Strong-Buy
Raymond James Financial, Inc.
Low
Report
0.9%
Date
Time
Symbol
Headline
Impact
12/3
07:01 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Dec 01 Filed by: WENDER JOSEPH H
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Dec 01 Filed by: WENDER JOSEPH H
12/1
06:46 pm
ions
Form 144/A IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
Low
Report
Form 144/A IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
12/1
06:14 pm
ions
Form 144 IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
Low
Report
Form 144 IONIS PHARMACEUTICALS Filed by: WENDER JOSEPH H
11/28
05:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: Devers Shannon L.
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: Devers Shannon L.
11/28
05:52 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: KLEIN JOSEPH III
Low
Report
Form 4 IONIS PHARMACEUTICALS For: Nov 25 Filed by: KLEIN JOSEPH III
11/25
05:53 pm
ions
Form 144 IONIS PHARMACEUTICALS Filed by: Devers Shannon L.
Low
Report
Form 144 IONIS PHARMACEUTICALS Filed by: Devers Shannon L.
11/25
04:04 pm
ions
Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III
Low
Report
Form 144 IONIS PHARMACEUTICALS Filed by: KLEIN JOSEPH III
11/20
05:12 pm
ions
Form 4 IONIS PHARMACEUTICALS For: Nov 19 Filed by: HERMAN JOAN E
Medium
Report
Form 4 IONIS PHARMACEUTICALS For: Nov 19 Filed by: HERMAN JOAN E
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 4 IONIS PHARMACEUTICALS For: Mar 19 Filed by: CROOKE STANLEY T
7.8%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
3/3 Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: O'NEIL PATRICK R. 7.6%
3/26 Ionis Pharmaceuticals Inc (NASDAQ: IONS) had its price target lowered by analysts at Cantor Fitzgerald from $65.00 to $56.00. They now have a "neutral" rating on the stock. 6.4%
4/8 Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs 4.9%
7/17 Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: McDevitt Damien 4.5%
9/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. 4.4%
4/23 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
2/16 Ionis Pharmaceuticals Looks Undervalued - Q4, FY Earnings Will Be Important [Seeking Alpha] 3.6%
9/10 Ionis Pharmaceuticals, Inc. (IONS) Presents at 17th Annual Morgan Stanley Global Healthcare Conference (Transcript) [Seeking Alpha] 3.2%
8/7 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.270 ActVsEst 0.260 - Beat 3.2%
TOP News Decliners
3/15
Researchers Behind Spinraza Win Breakthrough Prize [Forbes]
-9.9%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
7/22 Biogen Earnings: Here's What Investors Are Hoping To See In Report [Investor's Business Daily] -8.8%
3/10 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.0%
10/16 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.6%
3/20 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $49.00 price target on the stock. -5.4%
2/26 Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -4.9%
6/6 Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders -4.7%
9/30 Form 8-K IONIS PHARMACEUTICALS For: Sep 27 -4.6%
2/28 Ionis Pharmaceuticals Inc (NASDAQ: IONS) was upgraded by analysts at TheStreet from a "c" rating to a "b-" rating. -4.2%
12/16 Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: